HTL Biotechnology is a global leader in the development and production of innovative pharmaceutical-grade biopolymers, partnering with leading pharmaceutical and medical device companies to shape the future of aesthetic medicine.

A pioneer in the industrial bioproduction of hyaluronic acid, HTL Biotechnology has been combining scientific expertise, pharmaceutical excellence and industrial know-how for over 30 years.

With a unique compelling portfolio of biopolymers —hyaluronic acid, polynucleotides and human recombinant collagen III — HTL Biotechnology empowers aesthetics companies worldwide to develop next-generation solutions in regenerative aesthetics.

Driven by innovation, HTL Biotechnology continuously pushes the boundaries of biopolymer science, developing new molecules and advanced functionalization technologies to unlock new possibilities in aesthetic and regenerative medicine.

Shaping the future of aesthetics from within.